Abstract
Hemolytic Disease of the Newborn (HDN) can be a life threatening condition in Rh D positive babies born from Rh D negative mothers. For several decades, prophylactic treatment with immunoglobulins derived from human blood plasma from immunized donors has been available. Because of concerns for donor safety and limited supply of raw material, alternatives for production of specific immunoglobulins were investigated. Since 1994 ZLB has, in collaboration with a group at the University Hospital in Bern, started to develop recombinant anti-D antibodies. In 1997, a multidisciplinary team with expertise ranging from molecular biology to biochemical engineering for large scale operations was constituted, co-funded by the Swiss National Science Foundation and ZLB, as the industrial partner. The aims of this team are to establish the prophylactic principle and the manufacturing process for anti-D therapy based on recombinant antibody preparations produced from Chinese hamster ovary (CHO) cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1999 Kluwer Academic Publishers
About this chapter
Cite this chapter
Amstutz, H. et al. (1999). The SPP Biotech Module 1: Proteins for Medical Applications a Multidisciplinary Effort for the Development of a Recombinant Anti-RhD Antibody Preparation of Hemolytic Disease of the Newborn. In: Bernard, A., Griffiths, B., Noé, W., Wurm, F. (eds) Animal Cell Technology: Products from Cells, Cells as Products. Springer, Dordrecht. https://doi.org/10.1007/0-306-46875-1_96
Download citation
DOI: https://doi.org/10.1007/0-306-46875-1_96
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-6075-9
Online ISBN: 978-0-306-46875-9
eBook Packages: Springer Book Archive